Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J Diabetes Sci Technol ; 9(1): 69-76, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25261439

ABSTRACT

The oral glucose tolerance test (OGTT) is the only method to diagnose patients having impaired glucose tolerance (IGT), but its use has diminished considerably in recent years. Metabolomic profiling studies have identified a number of metabolites whose fasting levels are associated with dysglycemia and type 2 diabetes. These metabolites may serve as the basis of an alternative test for IGT. Using the stable isotope dilution technique, quantitative assays were developed for 23 candidate biomarker metabolites. These metabolites were measured in fasting plasma samples taken just prior to an OGTT from 1623 nondiabetic subjects: 955 from the Relationship between Insulin Sensitivity and Cardiovascular Disease Study (RISC Study; 11.7% IGT) and 668 subjects from the Diabetes Mellitus and Vascular Health Initiative (DMVhi) cohort from the DEXLIFE project (11.8% IGT). The associations between metabolites, anthropometric, and metabolic parameters and 2hPG values were assessed by Pearson correlation coefficients and Random Forest classification analysis to rank variables for their ability to distinguish IGT from normal glucose tolerance (NGT). Multivariate logistic regression models for estimating risk of IGT were developed and evaluated using AUCs calculated from the corresponding ROC curves. A model based on the fasting plasma levels of glucose, α-hydroxybutyric acid, ß-hydroxybutyric acid, 4-methyl-2-oxopentanoic acid, linoleoylglycerophosphocholine, oleic acid, serine and vitamin B5 was optimized in the RISC cohort (AUC = 0.82) and validated in the DMVhi cohort (AUC = 0.83). A novel, all-metabolite-based test is shown to be a discriminate marker of IGT. It requires only a single fasted blood draw and may serve as a more convenient surrogate for the OGTT or as a means of identifying subjects likely to be IGT.


Subject(s)
Biomarkers/analysis , Blood Glucose/analysis , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/metabolism , Glucose Intolerance/diagnosis , Glucose Intolerance/metabolism , Insulin Resistance , Adult , Aged , Biomarkers/metabolism , Cardiovascular Diseases/etiology , Cardiovascular Diseases/metabolism , Cohort Studies , Diabetes Mellitus, Type 2/complications , Female , Glucose Tolerance Test/standards , Humans , Male , Middle Aged , Predictive Value of Tests , Risk Factors
2.
Article in English | MEDLINE | ID: mdl-24984169

ABSTRACT

Our objective was to identify plasma biomarkers of ALS that can aid in distinguishing patients with ALS from those with disease mimics. In this multi-center study, plasma samples were collected from 172 patients recently diagnosed with ALS, 50 healthy controls, and 73 neurological disease mimics. Samples were analyzed using metabolomics. Using all identified biochemicals detected in > 50% of all samples in the metabolomics analysis, samples were classified as ALS or mimic with 65% sensitivity and 81% specificity by LASSO analysis (AUC of 0.76). A subset panel of 32 candidate biomarkers classified these diagnosis groups with a specificity of 90%/sensitivity 58% (AUC of 0.81). Creatinine was lower in subjects with lower revised ALS Functional Rating Scale (ALSFRS-R) scores. In conclusion, ALS can be distinguished from neurological disease mimics by global biochemical profiling of plasma samples. Our analysis identified ALS versus mimics with relatively high sensitivity. We identified a subset of 32 metabolites that identify patients with ALS with a high specificity. Interestingly, lower creatinine correlates significantly with a lower ALSFRS-R score. Finally, molecules previously reported to be important in disease pathophysiology, such as urate, are included in our metabolite panel.


Subject(s)
Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/diagnosis , Biomarkers/blood , Adult , Aged , Area Under Curve , Cohort Studies , Disease Progression , Female , Gas Chromatography-Mass Spectrometry , Humans , Male , Middle Aged , Neurologic Examination , Sensitivity and Specificity , Support Vector Machine
3.
Pediatr Pulmonol ; 49(5): 463-72, 2014 May.
Article in English | MEDLINE | ID: mdl-23847148

ABSTRACT

BACKGROUND: Cystic fibrosis (CF) is a multi-system disease affecting multiple organs and cells besides the respiratory system. Metabolomic profiling allows simultaneous detection of biochemicals originating from cells, organs, or exogenous origin that may be valuable for monitoring of disease severity or in diagnosis. AIM: We hypothesized that metabolomics using serum from children would differentiate CF from non-CF lung disease subjects and would provide insight into metabolism in CF. METHODS: Serum collected from children with CF (n = 31) and 31 age and gender matched children with other lung diseases was used for metabolomic profiling by gas- and liquid-chromatography. Relative concentration of metabolites was compared between the groups using partial least square discriminant analyses (PLS-DA) and linear modeling. RESULTS: A clear separation of the two groups was seen in PLS-DA. Linear model found that among the 459 detected metabolites 92 differed between CF and non-CF. These included known biochemicals in lipid metabolism, oxidants, and markers consistent with abnormalities in bile acid processing. Bacterial metabolites were identified and differed between the groups indicating intestinal dysbiosis in CF. As a novel finding several pathways were markedly different in CF, which jointly point towards decreased activity in the ß-oxidation of fatty acids. These pathways include low ketone bodies, low medium chain carnitines, elevated di-carboxylic acids and decreased 2-hydroxybutyrate from amino acid metabolism in CF compared to non-CF. CONCLUSION: Serum metabolomics discriminated CF from non-CF and show altered cellular energy metabolism in CF potentially reflecting mitochondrial dysfunction. Future studies are indicated to examine their relation to the underlying CF defect and their use as biomarkers for disease severity or for cystic fibrosis transmembrane regulator (CFTR) function in an era of CFTR modifying drugs.


Subject(s)
Cystic Fibrosis/metabolism , Energy Metabolism/physiology , Metabolome , Adolescent , Amino Acids/metabolism , Bile Acids and Salts/metabolism , Biomarkers/metabolism , Carnitine/blood , Case-Control Studies , Child , Child, Preschool , Chromatography, Gas , Chromatography, Liquid , Cystic Fibrosis/blood , Cystic Fibrosis/physiopathology , Dicarboxylic Acids/blood , Discriminant Analysis , Dysbiosis/blood , Fatty Acids/metabolism , Female , Humans , Hydroxybutyrates/blood , Infant , Ketone Bodies/blood , Linear Models , Lipid Metabolism/physiology , Male , Metabolomics , Microbiota/physiology , Oxidants/metabolism
4.
Obesity (Silver Spring) ; 21(12): E561-70, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23512965

ABSTRACT

OBJECTIVES: A spectrum of disorders including simple steatosis, nonalcoholic steatohepatitis, fibrosis, and cirrhosis is described by nonalcoholic fatty liver disease (NAFLD). With the increased prevalence of obesity, and consequently NAFLD, there is a need for novel therapeutics in this area. To facilitate this effort, a cellular model of hepatic steatosis was developed using HepaRG cells and the resulting biochemical alterations were determined. DESIGN AND METHODS: Using global metabolomic profiling, by means of a novel metabolite extraction procedure, the metabolic profiles in response to the saturated fatty acid palmitate, and a mixture of saturated and unsaturated fatty acids, palmitate and oleate (1:2) were examined. RESULTS: We observed elevated levels of the branched chain amino acids, tricarboxylic acid cycle intermediates, sphingosine and acylcarnitines, and reduced levels of carnitine in the steatotic HepaRG model with both palmitate and palmitate:oleate treatments. In addition, elevated levels of diacylglycerols and monoacylglycerols as well as altered bile acid metabolism were selectively displayed by palmitate-induced steatotic cells. CONCLUSIONS: Biochemical changes in pathways important in the transition to hepatic steatosis including insulin resistance, altered mitochondrial metabolism, and oxidative stress are revealed by this global metabolomic approach. Moreover, the utility of this in vitro model for investigating the mechanisms of steatotic progression, insulin resistance, and lipotoxicity in NAFLD was demonstrated.


Subject(s)
Fatty Liver/metabolism , Metabolome , Bile Acids and Salts/metabolism , Diglycerides/metabolism , Disease Progression , Fatty Liver/pathology , HEK293 Cells , Hep G2 Cells , Humans , Insulin/metabolism , Insulin Resistance , Liver/cytology , Liver/pathology , Mitochondria/metabolism , Monoglycerides/metabolism , Non-alcoholic Fatty Liver Disease , Oleic Acid/pharmacology , Oxidative Stress , Palmitic Acid/pharmacology , Phosphorylation , Reactive Oxygen Species/metabolism
5.
J Diabetes Sci Technol ; 7(1): 100-10, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23439165

ABSTRACT

BACKGROUND: Insulin resistance (IR) can precede the dysglycemic states of prediabetes and type 2 diabetes mellitus (T2DM) by a number of years and is an early marker of risk for metabolic and cardiovascular disease. There is an unmet need for a simple method to measure IR that can be used for routine screening, prospective study, risk assessment, and therapeutic monitoring. We have reported several metabolites whose fasting plasma levels correlated with insulin sensitivity. These metabolites were used in the development of a novel test for IR and prediabetes. METHODS: Data from the Relationship between Insulin Sensitivity and Cardiovascular Disease Study were used in an iterative process of algorithm development to define the best combination of metabolites for predicting the M value derived from the hyperinsulinemic euglycemic clamp, the gold standard measure of IR. Subjects were divided into a training set and a test set for algorithm development and validation. The resulting calculated M score, M(Q), was utilized to predict IR and the risk of progressing from normal glucose tolerance to impaired glucose tolerance (IGT) over a 3 year period. RESULTS: M(Q) correlated with actual M values, with an r value of 0.66. In addition, the test detects IR and predicts 3 year IGT progression with areas under the curve of 0.79 and 0.70, respectively, outperforming other simple measures such as fasting insulin, fasting glucose, homeostatic model assessment of IR, or body mass index. CONCLUSIONS: The result, Quantose(TM), is a simple test for IR based on a single fasting blood sample and may have value as an early indicator of risk for the development of prediabetes and T2DM.


Subject(s)
Blood Glucose/metabolism , Insulin Resistance , Prediabetic State/blood , Adult , Algorithms , Area Under Curve , Blood Glucose/analysis , Fasting/blood , Female , Humans , Insulin/blood , Male , Middle Aged
6.
Toxicol Appl Pharmacol ; 268(1): 79-89, 2013 Apr 01.
Article in English | MEDLINE | ID: mdl-23360887

ABSTRACT

Drug-induced liver injury (DILI) is a significant consideration for drug development. Current preclinical DILI assessment relying on histopathology and clinical chemistry has limitations in sensitivity and discordance with human. To gain insights on DILI pathogenesis and identify potential biomarkers for improved DILI detection, we performed untargeted metabolomic analyses on rats treated with thirteen known hepatotoxins causing various types of DILI: necrosis (acetaminophen, bendazac, cyclosporine A, carbon tetrachloride, ethionine), cholestasis (methapyrilene and naphthylisothiocyanate), steatosis (tetracycline and ticlopidine), and idiosyncratic (carbamazepine, chlorzoxasone, flutamide, and nimesulide) at two doses and two time points. Statistical analysis and pathway mapping of the nearly 1900 metabolites profiled in the plasma, urine, and liver revealed diverse time and dose dependent metabolic cascades leading to DILI by the hepatotoxins. The most consistent change induced by the hepatotoxins, detectable even at the early time point/low dose, was the significant elevations of a panel of bile acids in the plasma and urine, suggesting that DILI impaired hepatic bile acid uptake from the circulation. Furthermore, bile acid amidation in the hepatocytes was altered depending on the severity of the hepatotoxin-induced oxidative stress. The alteration of the bile acids was most evident by the necrosis and cholestasis hepatotoxins, with more subtle effects by the steatosis and idiosyncratic hepatotoxins. Taking together, our data suggest that the perturbation of bile acid homeostasis is an early event of DILI. Upon further validation, selected bile acids in the circulation could be potentially used as sensitive and early DILI preclinical biomarkers.


Subject(s)
Bile Acids and Salts/metabolism , Chemical and Drug Induced Liver Injury/metabolism , Oxidative Stress/physiology , Toxins, Biological/toxicity , Animals , Bile Acids and Salts/blood , Bile Acids and Salts/urine , Biomarkers/blood , Biomarkers/metabolism , Biomarkers/urine , Chromatography, High Pressure Liquid , Gas Chromatography-Mass Spectrometry , Hepatocytes/metabolism , Male , Metabolomics/methods , Random Allocation , Rats , Rats, Sprague-Dawley , Tandem Mass Spectrometry , Toxins, Biological/administration & dosage
7.
Annu Rev Med ; 64: 291-305, 2013.
Article in English | MEDLINE | ID: mdl-23327524

ABSTRACT

Metabolomics, the global interrogation of the biochemical components in a biological sample, has become an important complement to genomics and proteomics to aid in the understanding of pathophysiology. Major advantages of metabolomics are the size of the metabolome relative to the genome or proteome and the fact that it provides a view of the existing biochemical phenotype. As such, metabolomics is fast becoming an important discovery tool for new diagnostic and prognostic biomarkers. Although many methods exist for performing metabolomics, relatively few have led to successful development of new diagnostic tests. This review will aid the reader in understanding various metabolomic methods and their applications, as well as some of their inherent advantages and disadvantages. In addition, we present one example of the application of metabolomics to the identification of new fasting blood biomarkers for the diagnosis and monitoring of insulin resistance.


Subject(s)
Diabetes Mellitus/diagnosis , Insulin Resistance/physiology , Metabolomics/methods , Diabetes Mellitus/metabolism , Humans
8.
Genome Med ; 4(4): 33, 2012 Apr 30.
Article in English | MEDLINE | ID: mdl-22546470

ABSTRACT

BACKGROUND: Metabolomics, the non-targeted interrogation of small molecules in a biological sample, is an ideal technology for identifying diagnostic biomarkers. Current tissue extraction protocols involve sample destruction, precluding additional uses of the tissue. This is particularly problematic for high value samples with limited availability, such as clinical tumor biopsies that require structural preservation to histologically diagnose and gauge cancer aggressiveness. To overcome this limitation and increase the amount of information obtained from patient biopsies, we developed and characterized a workflow to perform metabolomic analysis and histological evaluation on the same biopsy sample. METHODS: Biopsies of ten human tissues (muscle, adrenal gland, colon, lung, pancreas, small intestine, spleen, stomach, prostate, kidney) were placed directly in a methanol solution to recover metabolites, precipitate proteins, and fix tissue. Following incubation, biopsies were removed from the solution and processed for histology. Kidney and prostate cancer tumor and benign biopsies were stained with hemotoxylin and eosin and prostate biopsies were subjected to PIN-4 immunohistochemistry. The methanolic extracts were analyzed for metabolites on GC/MS and LC/MS platforms. Raw mass spectrometry data files were automatically extracted using an informatics system that includes peak identification and metabolite identification software. RESULTS: Metabolites across all major biochemical classes (amino acids, peptides, carbohydrates, lipids, nucleotides, cofactors, xenobiotics) were measured. The number (ranging from 260 in prostate to 340 in colon) and identity of metabolites were comparable to results obtained with the current method requiring 30 mg ground tissue. Comparing relative levels of metabolites, cancer tumor from benign kidney and prostate biopsies could be distinguished. Successful histopathological analysis of biopsies by chemical staining (hematoxylin, eosin) and antibody binding (PIN-4, in prostate) showed cellular architecture and immunoreactivity were retained. CONCLUSIONS: Concurrent metabolite extraction and histological analysis of intact biopsies is amenable to the clinical workflow. Methanol fixation effectively preserves a wide range of tissues and is compatible with chemical staining and immunohistochemistry. The method offers an opportunity to augment histopathological diagnosis and tumor classification with quantitative measures of biochemicals in the same tissue sample. Since certain biochemicals have been shown to correlate with disease aggressiveness, this method should prove valuable as an adjunct to differentiate cancer aggressiveness.

9.
Amyotroph Lateral Scler ; 13(1): 110-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22117131

ABSTRACT

Our objective was to identify metabolic pathways affected by ALS using non-targeted metabolomics in plasma, comparing samples from healthy volunteers to those from ALS patients. This discovery could become the basis for the identification of therapeutic targets and diagnostic biomarkers of ALS. Two distinct cross-sectional studies were conducted. Plasma was collected from 62 (Study 1) and 99 (Study 2) participants meeting El Escorial criteria for possible, probable, or definite ALS; 69 (Study 1) and 48 (Study 2) healthy controls samples were collected. Global metabolic profiling was used to detect and evaluate biochemical signatures of ALS. Twenty-three metabolites were significantly altered in plasma from ALS patients in both studies. These metabolites include biochemicals in pathways associated with neuronal change, hypermetabolism, oxidative damage, and mitochondrial dysfunction, all of which are proposed disease mechanisms in ALS. The data also suggest possible hepatic dysfunction associated with ALS. In conclusion, the data presented here provide insight into the pathophysiology of ALS while suggesting promising areas of focus for future studies. The metabolomics approach can generate novel hypotheses regarding ALS disease mechanisms with the potential to identify therapeutic targets and novel diagnostic biomarkers.


Subject(s)
Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/physiopathology , Biomarkers/blood , Adult , Aged , Amyotrophic Lateral Sclerosis/drug therapy , Cross-Sectional Studies , Dietary Supplements , Female , Humans , Male , Metabolomics/methods , Middle Aged , Neuroprotective Agents/therapeutic use , Riluzole/therapeutic use
10.
J Cheminform ; 2(1): 9, 2010 Oct 18.
Article in English | MEDLINE | ID: mdl-20955607

ABSTRACT

BACKGROUND: Metabolomics experiments involve generating and comparing small molecule (metabolite) profiles from complex mixture samples to identify those metabolites that are modulated in altered states (e.g., disease, drug treatment, toxin exposure). One non-targeted metabolomics approach attempts to identify and interrogate all small molecules in a sample using GC or LC separation followed by MS or MSn detection. Analysis of the resulting large, multifaceted data sets to rapidly and accurately identify the metabolites is a challenging task that relies on the availability of chemical libraries of metabolite spectral signatures. A method for analyzing spectrometry data to identify and Quantify Individual Components in a Sample, (QUICS), enables generation of chemical library entries from known standards and, importantly, from unknown metabolites present in experimental samples but without a corresponding library entry. This method accounts for all ions in a sample spectrum, performs library matches, and allows review of the data to quality check library entries. The QUICS method identifies ions related to any given metabolite by correlating ion data across the complete set of experimental samples, thus revealing subtle spectral trends that may not be evident when viewing individual samples and are likely to be indicative of the presence of one or more otherwise obscured metabolites. RESULTS: LC-MS/MS or GC-MS data from 33 liver samples were analyzed simultaneously which exploited the inherent biological diversity of the samples and the largely non-covariant chemical nature of the metabolites when viewed over multiple samples. Ions were partitioned by both retention time (RT) and covariance which grouped ions from a single common underlying metabolite. This approach benefitted from using mass, time and intensity data in aggregate over the entire sample set to reject outliers and noise thereby producing higher quality chemical identities. The aggregated data was matched to reference chemical libraries to aid in identifying the ion set as a known metabolite or as a new unknown biochemical to be added to the library. CONCLUSION: The QUICS methodology enabled rapid, in-depth evaluation of all possible metabolites (known and unknown) within a set of samples to identify the metabolites and, for those that did not have an entry in the reference library, to create a library entry to identify that metabolite in future studies.

11.
J Biol Chem ; 285(40): 30516-22, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20675369

ABSTRACT

Cystic fibrosis (CF) is a life-shortening disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. To gain an understanding of the epithelial dysfunction associated with CF mutations and discover biomarkers for therapeutics development, untargeted metabolomic analysis was performed on primary human airway epithelial cell cultures from three separate cohorts of CF patients and non-CF subjects. Statistical analysis revealed a set of reproducible and significant metabolic differences between the CF and non-CF cells. Aside from changes that were consistent with known CF effects, such as diminished cellular regulation against oxidative stress and osmotic stress, new observations on the cellular metabolism in the disease were generated. In the CF cells, the levels of various purine nucleotides, which may function to regulate cellular responses via purinergic signaling, were significantly decreased. Furthermore, CF cells exhibited reduced glucose metabolism in glycolysis, pentose phosphate pathway, and sorbitol pathway, which may further exacerbate oxidative stress and limit the epithelial cell response to environmental pressure. Taken together, these findings reveal novel metabolic abnormalities associated with the CF pathological process and identify a panel of potential biomarkers for therapeutic development using this model system.


Subject(s)
Biomarkers/metabolism , Cystic Fibrosis/metabolism , Epithelial Cells/metabolism , Metabolomics , Respiratory Mucosa/metabolism , Carbohydrate Metabolism , Cohort Studies , Cystic Fibrosis/genetics , Cystic Fibrosis/pathology , Cystic Fibrosis/therapy , Cystic Fibrosis Transmembrane Conductance Regulator , Epithelial Cells/pathology , Female , Humans , Male , Mutation , Osmotic Pressure , Oxidative Stress , Purine Nucleosides/genetics , Purine Nucleosides/metabolism , Respiratory Mucosa/pathology
12.
PLoS One ; 5(5): e10883, 2010 May 28.
Article in English | MEDLINE | ID: mdl-20526369

ABSTRACT

BACKGROUND: Insulin resistance is a risk factor for type 2 diabetes and cardiovascular disease progression. Current diagnostic tests, such as glycemic indicators, have limitations in the early detection of insulin resistant individuals. We searched for novel biomarkers identifying these at-risk subjects. METHODS: Using mass spectrometry, non-targeted biochemical profiling was conducted in a cohort of 399 nondiabetic subjects representing a broad spectrum of insulin sensitivity and glucose tolerance (based on the hyperinsulinemic euglycemic clamp and oral glucose tolerance testing, respectively). RESULTS: Random forest statistical analysis selected alpha-hydroxybutyrate (alpha-HB) as the top-ranked biochemical for separating insulin resistant (lower third of the clamp-derived M(FFM) = 33 [12] micromol x min(-1) x kg(FFM) (-1), median [interquartile range], n = 140) from insulin sensitive subjects (M(FFM) = 66 [23] micromol x min(-1) x kg(FFM) (-1)) with a 76% accuracy. By targeted isotope dilution assay, plasma alpha-HB concentrations were reciprocally related to M(FFM); and by partition analysis, an alpha-HB value of 5 microg/ml was found to best separate insulin resistant from insulin sensitive subjects. alpha-HB also separated subjects with normal glucose tolerance from those with impaired fasting glycemia or impaired glucose tolerance independently of, and in an additive fashion to, insulin resistance. These associations were also independent of sex, age and BMI. Other metabolites from this global analysis that significantly correlated to insulin sensitivity included certain organic acid, amino acid, lysophospholipid, acylcarnitine and fatty acid species. Several metabolites are intermediates related to alpha-HB metabolism and biosynthesis. CONCLUSIONS: alpha-hydroxybutyrate is an early marker for both insulin resistance and impaired glucose regulation. The underlying biochemical mechanisms may involve increased lipid oxidation and oxidative stress.


Subject(s)
Diabetes Mellitus/metabolism , Glucose Intolerance/metabolism , Hydroxybutyrates/metabolism , Insulin Resistance , Adult , Biomarkers/metabolism , Blood Glucose/metabolism , Demography , Diabetes Mellitus/blood , Female , Humans , Male , Metabolome , Middle Aged , Models, Biological , Receptor, Insulin/metabolism
13.
FASEB J ; 24(8): 2962-75, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20371621

ABSTRACT

Choline is an essential nutrient, and deficiency causes liver and muscle dysfunction. Common genetic variations alter the risk of developing organ dysfunction when choline deficient, probably by causing metabolic inefficiencies that should be detectable even while ingesting a normal choline-adequate diet. We determined whether metabolomic profiling of plasma at baseline could predict whether humans will develop liver dysfunction when deprived of dietary choline. Fifty-three participants were fed a diet containing 550 mg choline/70 kg/d for 10 d and then fed < 50 mg choline/70 kg/d for up to 42 d. Participants who developed organ dysfunction on this diet were repleted with a choline-adequate diet for > or = 3 d. Plasma samples, obtained at baseline, end of depletion, and end of repletion, were used for targeted and nontargeted metabolomic profiling. Liver fat was assessed using magnetic resonance spectroscopy. Metabolomic profiling and targeted biochemical analyses were highly correlated for the analytes assessed by both procedures. In addition, we report relative concentration changes of other small molecules detected by the nontargeted metabolomic analysis after choline depletion. Finally, we show that metabolomic profiles of participants when they were consuming a control baseline diet could predict whether they would develop liver dysfunction when deprived of dietary choline.


Subject(s)
Choline Deficiency/complications , Liver Diseases/etiology , Metabolomics/methods , Predictive Value of Tests , Choline/administration & dosage , Diet , Fats/analysis , Humans , Liver/chemistry
14.
Bioanalysis ; 1(9): 1645-63, 2009 Dec.
Article in English | MEDLINE | ID: mdl-21083109

ABSTRACT

The identification of biomarkers of drug-induced kidney injury is an area of intensive focus in drug development. Traditional markers of renal function, including blood urea nitrogen and serum creatinine, are not region-specific and only increase significantly after substantial kidney injury. Therefore, more sensitive markers of kidney injury are needed. The ideal biomarkers will identify nephrotoxicity early in the drug-discovery process, resulting in decreased development costs and safer drugs. Metabolomics, the study of the small biochemicals present in a biological sample, has become a promising player in the nephrotoxicity arena. In this review, we describe the current status of the identification of metabolic biomarkers for drug-induced kidney toxicity screening. Many of these markers have been confirmed across multiple studies and can detect nephrotoxicity earlier than the traditional clinical chemistry and histopathology methods. Upon further validation, such markers will offer clear benefits for the pharmaceutical industry and regulatory agencies.


Subject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/diagnosis , Biomarkers, Pharmacological/analysis , Drug-Related Side Effects and Adverse Reactions/diagnosis , Kidney/drug effects , Metabolomics/methods , Animals , Biomarkers, Pharmacological/metabolism , Drug Design , Drug-Related Side Effects and Adverse Reactions/metabolism , Early Diagnosis , Female , Humans , Kidney Function Tests , Male , Mice , Rats
15.
Pharmacogenomics ; 9(4): 383-97, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18384253

ABSTRACT

OBJECTIVE: It is well established that disease states are associated with biochemical changes (e.g., diabetes/glucose, cardiovascular disease/cholesterol), as are responses to chemical agents (e.g., medications, toxins, xenobiotics). Recently, nontargeted methods have been used to identify the small molecules (metabolites) in a biological sample to uncover many of the biochemical changes associated with a disease state or chemical response. Given that these experimental results may be influenced by the composition of the cohort, in the present study we assessed the effects of age, sex and race on the relative concentrations of small molecules (metabolites) in the blood of healthy adults. METHODS: Using gas- and liquid-chromatography in combination with mass spectrometry, a nontargeted metabolomic analysis was performed on plasma collected from an age- and sex-balanced cohort of 269 individuals. RESULTS: Of the more than 300 unique compounds that were detected, significant changes in the relative concentration of more than 100 metabolites were associated with age. Many fewer differences were associated with sex and fewer still with race. Changes in protein, energy and lipid metabolism, as well as oxidative stress, were observed with increasing age. Tricarboxylic acid intermediates, creatine, essential and nonessential amino acids, urea, ornithine, polyamines and oxidative stress markers (e.g., oxoproline, hippurate) increased with age. Compounds related to lipid metabolism, including fatty acids, carnitine, beta-hydroxybutyrate and cholesterol, were lower in the blood of younger individuals. By contrast, relative concentrations of dehydroepiandrosterone-sulfate (a proposed antiaging androgen) were lowest in the oldest age group. Certain xenobiotics (e.g., caffeine) were higher in older subjects, possibly reflecting decreases in hepatic cytochrome P450 activity. CONCLUSIONS: Our nontargeted analytical approach detected a large number of metabolites, including those that were found to be statistically altered with age, sex or race. Age-associated changes were more pronounced than those related to differences in sex or race in the population group we studied. Age, sex and race can be confounding factors when comparing different groups in clinical studies. Future studies to determine the influence of diet, lifestyle and medication are also warranted.


Subject(s)
Metabolism/physiology , Plasma/metabolism , Adult , Age Factors , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Plasma/chemistry
16.
Pharmacogenomics ; 8(7): 863-6, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17638516

ABSTRACT

Metabolon is an emerging technology company developing proprietary analytical methods and software for biomarker discovery using metabolomics. The company's aim is to measure all small molecules (<1500 Da) in a biological sample. These small-molecule compounds include biochemicals of cellular metabolism and xenobiotics from diet and environment. Our proprietary mLIMStrade mark system contains advanced metabolomic software and automated data-processing tools that use a variety of data-analysis and quality-control algorithms to convert raw mass-spectrometry data to identified, quantitated compounds. Metabolon's primary focus is a fee-for-service business that exploits this technology for pharmaceutical and biotechnology companies, with additional clients in the consumer goods, cosmetics and agricultural industries. Fee-for-service studies are often collaborations with groups that employ a variety of technologies for biomarker discovery. Metabolon's goal is to develop technology that will automatically analyze any sample for the small-molecule components present and become a standard technology for applications in health and related sciences.


Subject(s)
Metabolism , Pharmacogenetics/methods , Drug Therapy/methods , Genetic Markers/genetics , Humans , Technology/trends
17.
Plant Mol Biol ; 53(5): 663-73, 2003 Nov.
Article in English | MEDLINE | ID: mdl-15010605

ABSTRACT

Appropriately regulated gene expression requires a suitable promoter. A number of promoters have been isolated and shown to be functional in plants, but only a few of them activate transcription of transgenes at high levels constitutively. We report here the cloning and characterization of a novel, constitutively expressed promoter isolated from Cestrum yellow leaf curling virus (CmYLCV), a double-stranded DNA plant pararetrovirus belonging to the Caulimoviridae family. The CmYLCV promoter is highly active in callus, meristems and vegetative and reproductive tissues in Arabidopsis thaliana, Nicotiana tabacum, Lycopersicon esculentum, Zea mays and Oryza sativa. Furthermore, the level of expression is comparable to, or higher than, that from the CaMV 35S, the 'super-promoter' or the maize ubiquitin 1 promoters, three frequently used promoters in agricultural biotechnology. The heritable, strong and constitutive activity in both monocotyledonous and dicotyledonous plants, combined with the extremely narrow CmYLCV host range, makes the CmYLCV promoter an attractive tool for regulating transgene expression in a wide variety of plant species.


Subject(s)
Caulimovirus/genetics , Cestrum/virology , Plants, Genetically Modified/genetics , Promoter Regions, Genetic/genetics , Arabidopsis/genetics , Arabidopsis/metabolism , Enzyme-Linked Immunosorbent Assay , Gene Dosage , Gene Expression , Glucuronidase/genetics , Glucuronidase/metabolism , Green Fluorescent Proteins , Histocytochemistry , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Solanum lycopersicum/genetics , Solanum lycopersicum/metabolism , Microscopy, Fluorescence , Oryza/genetics , Oryza/metabolism , Plasmids/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Nicotiana/genetics , Nicotiana/metabolism , Transgenes/genetics , Zea mays/genetics , Zea mays/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...